Detalles de la búsqueda
1.
CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration--in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window.
J Pharmacol Exp Ther
; 352(3): 568-78, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25576073
2.
Discovery, Multiparametric Optimization, and Solid-State Driven Identification of CHF-6550, a Novel Soft Dual Pharmacology Muscarinic Antagonist and ß2 Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases.
J Med Chem
; 2024 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38857426
3.
Discovery of Clinical Candidate CHF-6366: A Novel Super-soft Dual Pharmacology Muscarinic Antagonist and ß2 Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases.
J Med Chem
; 65(15): 10233-10250, 2022 08 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35901125
4.
Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases.
J Med Chem
; 60(24): 10026-10046, 2017 12 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-29200281
5.
Synthesis and anticonvulsant activity of a class of 2-amino 3-hydroxypropanamide and 2-aminoacetamide derivatives.
Bioorg Med Chem
; 14(10): 3263-74, 2006 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16460950
Resultados
1 -
5
de 5
1
Próxima >
>>